First Brands Group debt targeted by Apollo Global Management - report
Investing.com - H.C. Wainwright has reiterated its Buy rating and $2.50 price target on VolitionRX (NYSE:VNRX), currently trading at $0.64, following the company’s announcement of a new partnership with Werfen. According to InvestingPro data, analysts’ targets range from $2.00 to $5.00, suggesting significant upside potential despite the company’s current weak financial health score.
VolitionRX announced on Tuesday that it has entered a research license and exclusive commercial option rights agreement with Werfen’s Immunoassay Technology Center. Werfen, a global leader in in vitro diagnostics with $2.2 billion in revenue in 2024, will gain access to components of Volition’s proprietary Nu.Q H3.1 NETs assay. While VolitionRX’s revenue grew 35% in the last twelve months, InvestingPro analysis indicates the company is rapidly burning through cash, with short-term obligations exceeding liquid assets.
The agreement allows Werfen to investigate the clinical utility of Volition’s technology in managing Antiphospholipid Syndrome (APS) patients on its ACL AcuStar platform. APS affects approximately 4 million people worldwide and is currently diagnosed through blood tests requiring two positive results at least 12 weeks apart.
H.C. Wainwright noted that the agreement aligns with Volition’s strategy to out-license its proprietary Nu.Q NETs test to large global companies, leveraging their disease-specific knowledge, product development capabilities, regulatory experience, and installed base of proprietary analyzers.
The research firm expects Volition may announce additional human out-licensing deals in the coming weeks and months, with potential upfront and milestone payments as well as future recurring royalties potentially driving the company’s revenue growth. With current market capitalization at $68.5 million and analysts anticipating sales growth, these developments could be crucial for the company’s future performance.
In other recent news, VolitionRx Limited reported a 15% increase in revenue for Q2 2025, reaching over $400,000. This development underscores the company’s ongoing efforts to improve its financial performance, including a reduction in net cash usage for operating activities. VolitionRx has also emphasized its strategic focus on achieving cash neutrality by the end of 2025. Additionally, the company has signed a Research License and Exclusive Commercial Option Rights Agreement with Werfen’s Immunoassay Technology Center for Antiphospholipid Syndrome testing. This agreement allows Werfen access to Volition’s proprietary Nu.Q H3.1 NETs assay, with the potential for a future commercial launch under an exclusive license. These recent developments indicate VolitionRx’s commitment to advancing its financial and strategic goals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.